First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | June 2012 |
| End Date: | July 2013 |
| Contact: | Novartis Pharmaceuticals |
| Phone: | +1(800)340-6843 |
A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for
expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
Inclusion Criteria:
- Confirmed diagnosis of solid tumors
- 18 years or older
- ECOG performance status of 0, 1 or 2
- Adequate bone marrow, hepatic and renal function
- Obtained written informed consent
Exclusion Criteria:
- Patients with primary CNS tumor or CNS tumor involvement. However patients with CNS
metastases may be allowed if certain conditions are met.
- Major surgery within 4 weeks before study treatment
- Prior anaphylactic or other severe infusion reactions to human immunoglobulin or
antibody formulations
- Impaired cardiac functions
- Previous hepatitis viral infection such as hepatitis B or hepatitis C
- Diagnosis of HIV infection
- Pregnant or nursing (lactating) women
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials